Peptide News Digest

#Neurocrine

2 stories

Clinical Trials · View digest

Neurocrine CRENESSITY (Crinecerfont) Two-Year Pediatric CAH Data at ENDO 2026 Plus First Retrospective Case Series in 11β-Hydroxylase Subtype

Neurocrine Biosciences (Nasdaq: NBIX) presented two-year data from CAHtalyst Pediatric showing durable hormone control, reduced glucocorticoid exposure, and improved growth measures in pediatric patients with classic congenital adrenal hyperplasia (CAH), with weight, insulin resistance, and bone-age outcomes also improved at year 2. Separately, Neurocrine announced the first retrospective case series of CRENESSITY (crinecerfont) in patients with classic CAH due to 11β-hydroxylase deficiency, the second-most-common form of CAH after 21-hydroxylase deficiency, accounting for roughly 5% of cases. The 11β-OHD subtype was not previously studied in the crinecerfont trials and is characterized by cortisol deficiency plus excess adrenal androgens and accumulation of 11-deoxycortisol and 11-deoxycorticosterone. Crinecerfont is a small-molecule CRF1 receptor antagonist that dampens the CRH-ACTH peptide signaling axis.

Clinical Trials · View digest

Neurocrine Biosciences Presents Two-Year CRENESSITY Phase 3 Data at AACE 2026: 38% Glucocorticoid Dose Reduction in Classic CAH

Neurocrine Biosciences announced April 22 two-year data from the Phase 3 CAHtalyst Adult study at AACE 2026 in Las Vegas. CRENESSITY (crinecerfont), a CRF1 receptor antagonist that dampens the CRF-ACTH peptide signaling axis, achieved sustained glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia: mean daily GC dose decreased from 17.6 to 10.6 mg/m²/day HCe (−38%), and approximately 69% of patients achieved GC doses within the physiologic range while maintaining androgen control. No new safety signals emerged.